SBIR/STTR Research Award
Metalloproteinase Inhibitor For Pain and Morphine Tolerance Due To Thermal Injury
Award amount
$261,982Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- AQUILUS PHARMACEUTICALS INC
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- EM9ULMXK5F21
- Solicitation number
- PA13-088
- Topic code
- NIGMS
Research abstract
DESCRIPTION (provided by applicant): Aquilus Pharmaceuticals, Inc. proposes to evaluate the effects of a proprietary matrix metalloproteinase (MMP) inhibitor, AQU-010, for blocking neuropathic pain and morphine tolerance in a thermal injury (TI) rat model.The goals for Phase I are to scale-up the synthesis of AQU-010, determine its oral pharmacokinetics (PK) and target tissue penetration and then determine its efficacy in the TI-rat model of mechanical and thermal allodynia. A follow-up biomarker and gelatin zymography analysis will be performed to determine if any behavior changes observed from the animal model correspond to changes in metalloproteinase and/or cytokine levels. The ultimate goal of the proposed work is to evaluate whether a matrix metalloproteinase inhibitor can be used to treat pain and/or morphine tolerance in patients suffering from burn injuries without producing euphoria and addiction. PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE: An estimated 1.25 million individuals
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Matrix Metalloproteinase-2/-9 Inhibitor For The Treatment Of ALS
- Orally active MMP inhibitor for the treatment of bone cancer pain
- Development of a MMP Inhibitor for Neuropathic Pain
- Selective Matrix Metalloproteinase Inhibitors For Osteoarthritis
- MMP Inhibitor For Orofacial Pain
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Three-Dimensional Spatio-Temporal Control of Lipid Nanoparticle Manufacturing for Improved Nucleic Acid Delivery
- Paradigm-changing, versatile, scalable and cost-effective technology for monthly injections of peptide drugs
- Project MATCH: Multi-spectral AI/ML powered Burn and Wound Evaluation Technology using a Cost-Effective Handheld Device.
- A versatile platform to isolate cells from three-dimensional samples after spatial and temporal profiling
- Development of an Educational Product for Accelerating Solutions for Commercialization and Entrepreneurial Development (ASCEND) in Western IDeA States
Research funding history
6 SBIR/STTR records share this UEI (2011–2019). Reported award amounts total $3,562,237. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services